AKR1C3 and familial pancreatic carcinoma: Thus, a Phase 2 study of single-agent OBI-3424 is currently enrolling patients with locally advanced/metastatic pancreatic cancer, hepatocellular cancer, or other epithelial carcinomas with tumoral AKR1C3 overexpression.